Towards the end of June 2021, biopharmaceutical company AbbVie shared that Upadacitinib (RINVOQ) reached both its primary and all secondary endpoints in a Phase 3 maintenance study evaluating the therapy…
Thus far, retifanlimab, a drug designed to treat patients with anal cancer, has received Orphan Drug designation and Priority Review status. However, the approval process has not been entirely easy.…
Thanks to advances in immunotherapy, liver cancer (Hepatocellular carcinoma-HCC) has seen a rise in treatment options for patients in advanced stages of the disease. HCC is one of the…
It's no secret that illicit substance use, or substance use disorders, can cause a variety of health effects, including increased risks for certain diseases. As Parkinson's News Today recently reported,…
As reported in Physicians Weekly; a new study wanted to further characterize Enthesitis-related arthritis (ERA), a subtype of juvenile idiopathic arthritis (JIA) that is often is accompanied by anterior uveitis,…
In a story for the Urology Times, a panel of experts on the treatment of non-muscle invasive bladder cancer that is not responsive to Bacillus Calmette-Guérin (BCG) (which is commonly…
Clinical trial data is extremely helpful in understanding the safety, efficacy, and tolerability of various potential treatments. According to Muscular Dystrophy News, top-line data from the Phase 2b VISION-DMD…
In a video posted on Healio, Dr. Lorenzo D'Antiga from the Pappa Giovanni XXIII Hospital talked about the findings from a recent clinical study in which the drug odevixibat (also…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
